Favorable outcome in drug-resistant epilepsy with myoclonic-atonic seizures after cannabidiol introduction: a case report
Abstract
Case Presentation: A previously healthy male patient developed afebrile generalized tonic-clonic seizures at 3 years and 7 months of age. Over the following months, he evolved with multiple seizure types, including daily absence seizures and myoclonic-atonic seizures with drop attacks, leading to falls and head trauma. Initial neuroimaging showed no structural lesion. Serial electroencephalograms evolved to diffuse background disorganization, with frequent generalized spike-wave and polyspike-wave paroxysms. Despite valproate therapy and subsequent addition of ethosuximide, seizures persisted, requiring polytherapy after repeated hospitalizations. During this period, he developed neuropsychomotor regression, with language impairment, choking during medication administration and feeding, loss of motor skills, gait instability, and school withdrawal. Brain MRI disclosed nonspecific periventricular white matter abnormalities, without a structural epileptogenic lesion. At the peak of refractoriness, a 4:1 ketogenic diet was initiated during the last hospitalization. However, it was discontinued after three months because of poor adaptation and hypoglycemia. At that point, cannabidiol was introduced, after which the patient had no further seizures for 2 years and 5 months up to the current evaluation. From then on, there was progressive polypharmacy reduction and improvement in global development, with resolution of ataxia, recovery of motor coordination and school reintegration. At the latest evaluation, he remained seizure-free on cannabidiol, valproate, lamotrigine, levetiracetam, and phenobarbital. Discussion: Epilepsy with myoclonic-atonic seizures is a generalized childhood epilepsy, typically observed in previously healthy children, with peak incidence between 3 and 4 years of age. It is associated with multiple seizure types, recurrent falls, and, in more severe forms, neurodevelopmental regression and drug resistance. The present case fits this spectrum because of the age at onset, rapid diversification of seizures, absence of a structural epileptogenic lesion, and progressive electroencephalographic disorganization. Management remains challenging, with limited efficacy of conventional pharmacological regimens in clinical series, whereas ketogenic diet therapy and cannabidiol appear among the most relevant strategies in refractory cases. In this report, ketogenic diet had short duration and was discontinued because of clinical intolerance, whereas after cannabidiol introduction, absence of seizures for 2 years and 5 months was observed, accompanied by functional improvement and progressive polypharmacy reduction. Final Comments: This case illustrates the complexity of drug-resistant epilepsy with myoclonic-atonic seizures, particularly when accompanied by neurodevelopmental regression and polytherapy. It documents a favorable course after cannabidiol introduction with subsequent therapeutic simplification, and may inform discussion of adjunctive strategies in similar cases.